Skip to main content

Lucira Health, Inc.

LHDXDelisted Apr 12, 2023
Industry
In Vitro & In Vivo Diagnostic Substances
SEC CIK
0001652724

Lucira Health, Inc. was delisted on Apr 12, 2023; its insiders filed their last Form 4 on Mar 13, 2023; 29 institutions reported holding it in 13F filings for Q4 2022, worth $1.04M in total; no superinvestor held it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 1:51 PM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of Lucira Health, Inc., annual
Line itemFY2021!
Period endDec 31, 2021
Filing10-K
ReportedJan 10, 2022
Revenue$93.1M
Cost of revenue$81.4M
Gross profit$10.2M
Operating expenses$75.4M
Research and development$39.8M
Selling, general and administrative$35.5M
Operating income-$65.1M
Interest expense$3.00K
Income tax$17.0K
Net income-$64.8M
Margins and growth
Gross margin11.0%
Operating margin-70.0%
Net margin-69.7%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Lucira Health, Inc., annual
Line itemFY2021
Period endDec 31, 2021
Filing10-K
ReportedJan 10, 2022
Cash and equivalents$106.0M
Accounts receivable$27.2M
Inventory$50.8M
Total current assets$206.3M
Property, plant and equipment$31.0M
Total assets$240.4M
Accounts payable$19.4M
Total current liabilities$50.3M
Total liabilities$51.6M
Shareholders' equity$188.8M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Lucira Health, Inc., annual
Line itemFY2021
Period endDec 31, 2021
Filing10-K
ReportedJan 10, 2022
Operating cash flow-$100.9M
Capital expenditures$15.4M
Free cash flow-$116.3M
Depreciation and amortization$3.67M
Stock-based compensation$8.11M
Investing cash flow-$15.4M
Financing cash flow$161.7M
Net change in cash$45.4M
Ratio
Stock-based compensation, % of revenue8.7%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Lucira Health, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Nov 7, 202240.6M+3.5%SEC
Aug 8, 202240.1M+3.6%SEC
May 11, 202239.9M+3.4%SEC
Mar 28, 202239.8M+3.2%SEC
Nov 8, 202139.2M–SEC
Aug 10, 202138.7M–SEC
May 10, 202138.6M–SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
  • A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.